Needham & Company
-
Needham Reiterates Hold Rating on Globus Medical (GMED)
-
Needham Reiterates Hold Rating on Globus Medical (GMED)
-
Globus Medical (GMED) PT Raised to $82 at Needham & Company
-
Globus Medical (GMED) Offers Light Guidance but Needham Sees Through Chatter and Raises PT to $75
-
Globus Medical (GMED) PT Raised to $63 at Needham & Company
-
Globus Medical (GMED) PT Raised to $56 at Needham & Company
-
Globus Medical (GMED) PT Lowered to $57 at Needham & Company
-
Globus Medical (GMED) PT Raised to $65 at Needham & Company
-
Globus Medical (GMED) PT Raised to $58 at Needham & Company
-
Needham & Company Upgrades Globus Medical (GMED) to Buy
-
K2M Warning is a Negative Read-Through for Globus Medical (GMED) and NuVasive (NUVA) - Needham & Company
-
UPDATE: Needham & Company Starts Globus Medical (GMED) at Hold
-
Notable Analyst Rating Changes 9/11: (VRA) (WCC) (AAWW) Upgraded; (M) (EOPN) (ESRX) Downgraded

